EASL 2026 closed in Barcelona on May 30 after a week that reshaped two liver-disease narratives. On MASH: the GLP-1/glucagon peptide cohort (survodutide NEJM 47-62% MASH improvement, pemvidutide Best of EASL with cardiometabolic and fibrosis data, MetaVia DA-1726 9.1% weight loss) competed against THR-β agonism (Madrigal Rezdiffra, Aligos ALG-055009 46% liver fat), RNAi (Arrowhead ARO-INHBE), and FGF21 analogs (the Akero and 89bio programs that drew $5.2B and $3.5B acquisitions). On HBV/HDV: the entry-inhibitor peptides (Gilead's newly approved bulevirtide, Assembly's oral ABI-6250) shared the stage with gene editing (Precision PBGENE-HBV cccDNA elimination), epigenetic silencing (TUNE-401), capsid modulation plus ASO sequencing (Aligos), and therapeutic vaccines (Brii BRII-179). The combined week confirmed that liver disease is now a multi-mechanism therapeutic arena where peptides anchor the metabolic and entry-inhibitor lanes while gene and immune modalities pursue functional cure. ADA 2026 (June 5-8 New Orleans) is the next major readout window for the metabolic-peptide side.
EASL 2026 wraps in Barcelona Saturday May 30 after a week that confirmed MASH as a multi-mechanism therapeutic battleground. The GLP-1/glucagon peptide cohort delivered the headline data: Boehringer Ingelheim's survodutide full 48-week Phase 2 results in the NEJM (47-62% MASH improvement without fibrosis worsening, Phase 3 LIVERAGE enrolling); Altimmune's pemvidutide 48-week IMPACT data selected 'Best of EASL 2026' (triglycerides -23.7%, weight -7.5%, with HistoIndex qFibrosis fibrosis regression); MetaVia DA-1726 higher-dose Phase 1. The non-peptide cohort: Madrigal Rezdiffra eight-poster cardiovascular and portal-hypertension data, Aligos ALG-055009 THR-β (46.2% liver fat), Arrowhead ARO-INHBE RNAi (44% liver fat plus tirzepatide combination doubling weight loss), Galectin belapectin, Sagimet denifanstat. Novo Nordisk's ESSENCE Japanese and menopausal subgroups plus real-world burden data anchored the semaglutide MASH-labeling case. The week established that no single mechanism dominates MASH — GLP-1/glucagon leads on combined weight-plus-liver effect, THR-β and FGF21 lead on direct antifibrotic action, and combination therapy is the emerging 2027-2028 thesis.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
The Memorial Day week landing pad in the medical-conference calendar is unusually peptide-heavy. Monday May 25 is the US Memorial Day federal holiday. EASL 2026 (European Association for the Study of the Liver) opens Wednesday May 27 in Barcelona running through Saturday May 30, with Novo Nordisk's ESSENCE Phase 3 liver-safety analyses, Eli Lilly's retatrutide MASLD Phase 3 enrollment status, Boehringer survodutide SYNCHRONIZE-1 forward-look, and MetaVia vanoglipel + resmetirom MASH preclinical work anchoring the peptide-relevant program. ASCO 2026 (American Society of Clinical Oncology) opens Friday May 29 in Chicago running through Tuesday June 2 with the peptide-oncology slate landing across all five days. Combined, the two meetings concentrate the most peptide-mechanism data of any week in 2026 — MASH plus oncology back-to-back. Practitioner press will be split across the two meetings.
The European Association for the Study of the Liver (EASL) Congress 2026 opens Wednesday May 27 in Barcelona with a heavy peptide-MASH slate. Novo Nordisk's ESSENCE Phase 3 program leads with liver-safety subgroup analyses (Japanese MASH cohort, women in menopause), building on the August 2025 FDA approval of semaglutide for MASH-with-fibrosis. Eli Lilly's retatrutide MASLD Phase 3 (NCT06859268) is enrolling on the 86% Phase 2 liver-fat reduction baseline. Boehringer Ingelheim survodutide SYNCHRONIZE-1 Phase 3 MASH data is expected late 2026 with positive results potentially establishing the GLP-1/glucagon dual agonist as standard of care alternative to semaglutide. MetaVia's vanoglipel (DA-1241, GPR119 agonist) Phase 2a + resmetirom combination work presented at ECO 2025 anchors the combination-MASH therapy thesis. The EASL plenaries plus the May 21 TRIUMPH-1 readout reframe MASH as a peptide-mechanism battleground rather than a single-drug indication.